Zoetis Inc. (NYSE:ZTS) Stock Has Average Target Price of $101.08 According to Brokerages

Posted by Geri Gentry on Oct 4th, 2026

Shares of Zoetis Inc. (NYSE:ZTS – Get Free Report) have been assigned an average recommendation of “Hold” from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $101.08.

ZTS has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Zoetis in a research report on Wednesday, September 9th. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research report on Friday, August 7th. William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. TD Cowen cut their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Finally, Citigroup decreased their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th.

Get Our Latest Research Report on Zoetis

Zoetis Trading Up 0.8%

NYSE ZTS opened at $69.62 on Thursday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The business has a fifty day simple moving average of $74.39 and a 200 day simple moving average of $86.44. Zoetis has a 12 month low of $68.77 and a 12 month high of $148.79. The firm has a market capitalization of $28.77 billion, a P/E ratio of 11.47, a PEG ratio of 1.63 and a beta of 0.74.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm earned $1.76 EPS. The business’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts predict that Zoetis will post 6.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Large investors have recently made changes to their positions in the business. J. Stern & Co. LLP increased its stake in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. Flossbach Von Storch SE purchased a new position in Zoetis in the second quarter valued at approximately $302,601,000. BlackRock Inc. lifted its stake in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new position in Zoetis during the first quarter valued at $286,660,000. Finally, Van ECK Associates Corp grew its holdings in Zoetis by 269.0% during the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after purchasing an additional 1,740,113 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

(Get Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.